GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Newron Pharmaceuticals SpA (XTER:NP5) » Definitions » Capex-to-Revenue

Newron Pharmaceuticals SpA (XTER:NP5) Capex-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Newron Pharmaceuticals SpA Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Newron Pharmaceuticals SpA's Capital Expenditure for the six months ended in Jun. 2024 was €-0.01 Mil. Its Revenue for the six months ended in Jun. 2024 was €3.41 Mil.

Hence, Newron Pharmaceuticals SpA's Capex-to-Revenue for the six months ended in Jun. 2024 was 0.00.


Newron Pharmaceuticals SpA Capex-to-Revenue Historical Data

The historical data trend for Newron Pharmaceuticals SpA's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newron Pharmaceuticals SpA Capex-to-Revenue Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - - -

Newron Pharmaceuticals SpA Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Newron Pharmaceuticals SpA's Capex-to-Revenue

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newron Pharmaceuticals SpA's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Capex-to-Revenue falls into.



Newron Pharmaceuticals SpA Capex-to-Revenue Calculation

Newron Pharmaceuticals SpA's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.011) / 9.057
=0.00

Newron Pharmaceuticals SpA's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.007) / 3.407
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Newron Pharmaceuticals SpA  (XTER:NP5) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Newron Pharmaceuticals SpA Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Newron Pharmaceuticals SpA Business Description

Traded in Other Exchanges
Address
Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
Executives
Stefan Weber Board of Directors
Dr. Ulrich Köstlin Supervisory Board

Newron Pharmaceuticals SpA Headlines

No Headlines